UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +1
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange on which registered | ||
Ordinary Shares, par value NIS0.01 per share |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
On August 14, 2024, UroGen Pharma Ltd. announced that it completed its submission to the U.S. Food and Drug Administration of its New Drug Application for UGN-102 for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 15, 2024 | UROGEN PHARMA LTD. | |||||
By: | /s/ Don Kim | |||||
Don Kim | ||||||
Chief Financial Officer |
Document and Entity Information |
Aug. 14, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001668243 |
Document Type | 8-K |
Document Period End Date | Aug. 14, 2024 |
Entity Registrant Name | UROGEN PHARMA LTD. |
Entity Incorporation State Country Code | L3 |
Entity File Number | 001-38079 |
Entity Tax Identification Number | 98-1460746 |
Entity Address, Address Line One | 400 Alexander Park Drive |
Entity Address, Address Line Two | 4th Floor |
Entity Address, City or Town | Princeton |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08540 |
City Area Code | (646) |
Local Phone Number | 768-9780 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Ordinary Shares, par value NIS0.01 per share |
Trading Symbol | URGN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end